Day Zero Diagnostics
A medical, clinical and regulatory affairs professional with over 25 years of experience in the development, design, and implementation of phase I-IV clinical trials of IVDs and therapeutic devices. The architect of multiple successful regulatory submissions to the FDA and international authorities, including IDE, 510(k), de novo, PMA and CE. She has a BA from Cornell University and a PhD from the University of Cincinnati.
This person is not in the org chart
This person is not in any offices
Day Zero Diagnostics
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and the proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale.